<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049448</url>
  </required_header>
  <id_info>
    <org_study_id>ABX464-302</org_study_id>
    <nct_id>NCT04049448</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abivax S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abivax S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2a open-label study to evaluate the long-term safety and efficacy of ABX464 50mg as&#xD;
      maintenance therapy in patients with moderate to severe rheumatoid arthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2a open-label study aims at investigating the long-term safety and efficacy of an&#xD;
      oral dose of ABX464 in patients who have been previously enrolled in the ABX464-301 clinical&#xD;
      study and who are willing to continue their treatment.&#xD;
&#xD;
      All patients will receive ABX464 given at 50mg o.d. irrespectively of their previous&#xD;
      treatment received in the ABX464-301 study (i.e. ABX464 or Placebo).&#xD;
&#xD;
      The enrolment in this follow-up study will be based on the willingness of the subject to&#xD;
      carry on his/her participation and also based on investigator's judgement.&#xD;
&#xD;
      Patients will be treated with ABX464 for a period of 52 weeks. If they achieve a clinical&#xD;
      response on Week 52 (defined as DAS28-CRP ≤ 2,6 for anti-TNFα naïve patients or DAS-28-CRP ≤&#xD;
      3,2 for patients previously treated by anti-TNFα), they will be eligible to continue&#xD;
      treatment for up to 104 weeks.Patients will be followed up at week , week 2 and then, on a&#xD;
      monthly basis the first year (up to W52), and quaterly the second year (up to W104).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, follow-up study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events in the ABX464 treated Patients, categorized by severity</measure>
    <time_frame>through study completion (average of 104 weeks)</time_frame>
    <description>Incidence of adverse events emerging during the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Low Disease Activity (LDA)</measure>
    <time_frame>Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104</time_frame>
    <description>Low Disease Activity (LDA) is defined as DAS28-ESR &lt;=3.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission</measure>
    <time_frame>Week 4, Week 12, Week24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104</time_frame>
    <description>The ACR/EULAR boolean-based remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Simplified Disease Activity Score (SDAI) remission</measure>
    <time_frame>Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104</time_frame>
    <description>The SDAI remission is considered achieved if the SDAI score ≤ 3.3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Clinical Disease Activity (CDAI) remission</measure>
    <time_frame>Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104</time_frame>
    <description>The CDAI remission is considered achieved if the CDAI score ≤ 2.8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving ACR20/50/70 response</measure>
    <time_frame>Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104</time_frame>
    <description>The categorical American College of Rheumatology 20% or 50% or 70% (ACR20/50/70) response is a validated index of rheumatoid arthritis disease activity, defined by the number of patients who achieved at least 20% or 50% or 70% improvement in the ACR response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving categorical Disease Activity Scores (DAS) (measured on 28 joints) - C-Reactive Protein (DAS28-CRP) response</measure>
    <time_frame>Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104</time_frame>
    <description>Proportion of patients achieving categorical Disease Activity Score (DAS) DAS28-C-Reactive Protein (CRP) [DAS28-CRP] response will be measured as moderate/good European League Against Rheumatism (EULAR) response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of the Low Disease Activity (LDA) remission</measure>
    <time_frame>up to 104 weeks</time_frame>
    <description>time when DAS28-ESR &lt;=3.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission</measure>
    <time_frame>up to 104 weeks</time_frame>
    <description>The ACR/EULAR remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1.&#xD;
Time to onset will be when this criteria will be ≤ 1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ABX464 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX464</intervention_name>
    <description>All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).</description>
    <arm_group_label>ABX464 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients previously enrolled in the ABX464-301 clinical study who have completed the&#xD;
             initial 12 weeks of treatment period;&#xD;
&#xD;
        Criteria that should be met by patients at week 52 to be eligible for 52 additional weeks&#xD;
        of study treatment:&#xD;
&#xD;
        ▪ Patients should be in clinical response. Clinical response is defined as: DAS28-CRP ≤ 2,6&#xD;
        for anti-TNFα naïve patients or DAS-28-CRP ≤ 3,2 for patients previously treated by&#xD;
        anti-TNFα.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition, which in the opinion of the investigator, could compromise the&#xD;
             patient's safety or adherence to the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul GINESTE, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Abivax S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Jan Palfijn</name>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Tomayerova nemocnice</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest - Hôpital Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU DE MONTPELLIER - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHR Mulhouse Sud-Alsace</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Tours - Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complex Medical Centre - Déli Klinika</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Ltd.</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMed Rehabilitációs és Diagnosztikai Központ</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk, Nowak Sp. J.</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pratia MCM</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespół Poradni Specjalistycznych REUMED</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Lecznica MAK-MED S.C.</name>
      <address>
        <city>Nadarzyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Hetmańska</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Geriatrics</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHEUMA MEDICUS Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>moderate to severe Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

